MOSCOW (Kashmir English): Russia has declared the creation of Enteromix, the first global cancer vaccine based on mRNA technology, which is 100% effective and safe in clinical trials.
The breakthrough is being described as a huge medical breakthrough, providing fresh hope to millions of cancer patients worldwide.
Clinical Trials Results and Side Effects
Researchers say that Enteromix has already been introduced into phase-one clinical application in some of Russia’s top oncology centers while it awaits final approval by the Health Ministry for nationwide distribution.
As it underwent clinical trials, the vaccine did not have any major side effects, a far cry from traditional cancer therapy like chemotherapy and radiation that induce serious side effects such as hair loss, exhaustion, and organ harm.
The vaccine takes advantage of mRNA technology, the same platform used in several COVID-19 vaccines.
The approach allows the body’s own cells to manufacture proteins that mimic proteins present on cancer cells, preconditioning the immune system to target and eliminate cancerous cells specifically.
Unlike conventional treatments, Enteromix acts selectively on tumors, avoiding healthy tissue and substantially enhancing patient tolerance.
Enteromix is given by an uncomplicated intramuscular injection, which is less invasive than the sophisticated cancer therapies used today.
It was designed by the National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB), two of Russia’s top institutions in the field of oncology and molecular medicine. Potential Beneficiaries
Experts say Enteromix has the potential to treat a broad range of patients, including those with lung, breast, colorectal, and pancreatic cancers.
It could also present new choices for patients with hereditary cancer syndromes like BRCA1/2 mutations, those who have tumor resistance to chemotherapy, and even immunocompromised patients who generally have problems with traditional treatments.
A New Era in Cancer Care
If clearance is approved, Enteromix may be a game-changer in worldwide oncology, providing patients with a choice to harsh therapies and improving survival rates and quality of life.
Oncologists believe that such vaccines could lead to a new era of precision therapy, converting cancer therapy from generalized medications to tailor-made, precise treatment.
